In the pharmaceutical industry risk assessments of chronic cardiac safety liabilities are mostly performed during late stages of preclinical drug development using in vivo animal models. Here, we explored the potential of human induced pluripotent stem cell-derived cardiomyocytes (hiPS-CMs) to detect chronic cardiac risks such as drug-induced cardiomyocyte toxicity.
Introduction
Cardiac drug safety is an important stage within drug development and is essential for the advancement of novel drug candidates. The primary focus is on acute electrophysiological de-risking (i.e. hERG inhibition) to detect liabilities that might translate into QT-prolongation and cardiac arrhythmias in humans. However, less attention is paid to the delayed cardiac liabilities that are currently identified in the more costly, late-phase toxicity studies using in vivo models, or in the worst cases within clinical development or on the market (Laverty et al., 2011; McNaughton et al., 2014) . Furthermore, it is believed that one of the major factors contributing to the limited success of predicting clinical toxicities is the translatability across preclinical (animal) models into humans. In contrast, human induced pluripotent stem cell-derived cardiomyocytes (hiPS-CMs) are expected to better reflect the physiology and pharmacology of human cardiomyocytes and, therefore, have been increasingly utilized to evaluate acute cardiac risks and lately also chronic (structural) cardiotoxicity (Gintant et al., 2016) . At present, drug-induced chronic liabilities (e.g. cardiotoxicity) are risks that are not investigated so much, but are highly relevant to further improve cardiac risk assessment within drug discovery and development.
Video microscopy-based motion field imaging analysis is able to characterize motion-derived contractile properties of cardiomyocytes (Ahola et al., 2014; Hayakawa et al., 2014; Maddah et al., 2015) in a non-invasive manner. Motion field imaging has been demonstrated to detect acute (<1 h) druginduced effects of cardiac ion channel drugs in hiPS-CMs (Hayakawa et al., 2014) . Application of this technology to chronic drug-induced effects on cardiac cell models has been less explored. In the present study, we investigated delayed/chronic effects (over 72 h) of cardiotoxic drugs, by simultaneously measuring (i) functional motion field imaging together with (ii) analysis of cardiac biomarkers and (iii) transcriptional expression from the same experiment (Figure 1 ).
Cardiac proteins such as cardiac troponin I (cTnI) and fatty acid binding protein 3 (FABP3) are well-established serum biomarkers for the clinical assessment and monitoring of cardiac toxicity and myocardial injury (Adamcová et al., 2005; Pelsers et al., 2005; Walker, 2006) . Furthermore, N-terminal pro brain natriuretic peptide (NT-proBNP) is the benchmark for the clinical assessment of drug-induced left ventricular dysfunction and heart failure (Seino et al., 2004; Kang et al., 2015) . In the present study, we evaluated the translational value of these biomarkers for cardiotoxicity in hiPS-CMs. We studied different classes of drugs (doxorubicin, arsenic trioxide and panobinostat) known to be associated with chronic cardiac adverse effects in humans (Swain et al., 2003; Sharma et al., 2013; Alamolhodaei et al., 2015) . Ebastine was chosen as a negative control as it has no reported, cardiac side effects in the clinic (Moss and Morganroth, 1999) .
Thus, the aim of this study was to evaluate motion field imaging as a tool to assess chronic drug-induced effects on the contractile properties of hiPS-CMs. Furthermore, we wanted to understand the role and value of concurrent measurements of cardiac biomarkers under different cardiotoxic conditions, supported by transcriptional profiling in the same hiPS-CMs. Assessing the relationships between the different measures allowed us to evaluate the value of video motion imaging and cardiac toxicity biomarkers as predictive tools for chronic drug-induced responses using hiPS-CMs.
Methods

Experimental design
The goal of the study was to evaluate measurements of functional parameters, biomarkers and gene expression data originating from the same experiment (well) (Figure 1 ). Although this approach comes with certain limitations (e.g. specific time points for biomarker and gene
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Panobinostat expression sampling), it provides insight into the relationship between different parameters/approaches. To investigate drug-related effects on the contractile kinetics of hiPS-CMs, we applied video microscopy motion analysis. Sampling motion field imaging over 72 h after the initial drug administration yielded the following parameters of interest: maximal contraction velocity (CV), maximal relaxation velocity (RV), contraction-relaxation duration (CRD), beat rate (BR) and beat area (BA) (Figure 1 ). Collection of medium for analysis of cardiac biomarkers (cTnI, FABP3 and NT-proBNP) was determined at the 24, 48 and 72 h time points (during obligatory medium exchanges), whereas samples for transcriptional profiling were collected at the end of the experiment immediately after the 72 h recording. N values (n = 5) represent data from individual wells each containing a monolayer of hiPS-CMs (approximately 20 000 cells). hiPS-CMs (batch CB156CL) were cultured on two separate occasions. All experiments were done non-blinded. Researchers who performed and/or analysed a specific assay (video microscopy, biomarkers and microarray) were unaware of the other results and conclusions at the time of their experiments. A quality control (QC) was done on all data and figures presubmission. Data and statistical analysis complied with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015) .
Cell culture and reagents
hiPS-CM were purchased from Axiogenesis (Cor.4 U® cardiomyocytes, Ax-B-HC02-1 M, Germany) as frozen vials (batch CB156CL). Cor.4 U® cardiomyocytes contain a mix of 60% ventricular and 40% atrial and nodal cells, whereas non-myocytes represent less than 0.5% of the hiPS-CM culture. Frozen vials containing 6-week-old hiPS-CMs cultures were cultured for an additional 7 days postthawing, which is necessary for these cells to reach functional maturation (e.g. synchronic beating and expression of important cardiac ion channels and calcium handling proteins). Frozen vials were thawed and cultured in a humidified incubator at 37°C and 5% CO 2 according to the manufacturer's instructions. Briefly, cardiomyocytes were thawed in thawing medium, seeded onto fibronectincoated T-25 flasks (Greiner) and cultured using culture medium supplemented with ciprofloxacin (1 μg·mL À1 ).
Figure 1
Experimental design for evaluation of chronic drug-induced cardiac liabilities in hiPS-CMs. Cartoon depicting the combined measurement of hiPSCMs characteristics using video microscopy, biomarkers and gene expression. The inset at the bottom represents a single beat period of the selected beating area, containing a contraction phase followed by the relaxation phase of hiPS-CMs.
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Video microscopy and motion vector analysis
The functional beating properties of cardiomyocytes were assessed through video microscopy using the Sony SI8000 motion field imaging system (Hayakawa et al., 2014) . Video imaging of beating hiPS-CMs was recorded for 10 s at a frame rate of 150 fps, a resolution of 2048 × 2048 pixels and a depth of 8 bits using a 10× objective. Recordings were done at baseline and 4, 12, 24, 48 and 72 h after initial compound treatment. For each well, a region of interest was selected that contained a confluent monolayer of beating cells. Removal of the plate for compound addition and medium exchange did not influence the position or the coordinates of the plate within the SI8000 system, allowing assessment of the same region of interest during the entire experiment. Motion vectors of beating hiPS-CMs were obtained using a block matching algorithm. The Sony SI8000 analysis software was used to analyse functional parameters (BA, BR, CV, RV and CRD) from the averaged motion waveforms obtained from all the contractions measured during the respective 10 s recording.
Biomarker analysis
For each treatment condition, cell medium was collected 24, 48 and 72 h after initial addition of compounds or vehicles. There were no samples collected before compound treatments. Collected medium was centrifuged at 12000 × g for 5 min. Samples were kept frozen at approximately À80°C until analysis. NT-proBNP, cTnI and FABP3 were measured using the Milliplex human cardiovascular disease magnetic bead panel 1 (Millipore -HCVD1MAG-67 K) on a Magpix instrument (Luminex). The multiplex protocol was executed according to manufacturer's instructions with the exception that the stock standard was serially diluted in culture medium. In the plate wells, standard curve samples were compensated with assay buffer, and kit QC samples were compensated with the respective medium. The lower and upper limits of quantification (LLOQ and ULOQ) were 34.3 and 25 000-pg·mL
À1
, respectively, for NT-proBNP; 137 and 100 000-pg·mL À1 , respectively, for FABP3; and 68.6 and 50 000 pg·mL
, respectively, for cTnI. Results below the LLOQ were replaced by the LLOQ value in the calculation of averages.
Statistical analysis of video motion-based contractile properties and cardiac serum biomarkers
Statistical analysis of video microscopy-related parameters was done using repeated measures ANOVA. The baseline measurement was taken pre-dosing while the other measurements were taken at 4, 12, 48 and 72 h post-dosing. The analysis was performed for variety in reading on the 'δ changes' as calculated by subtracting the measured baseline value from the corresponding measured value at a certain time point. Correlations between functional parameters are represented using the Pearson correlation coefficient r, where 0 represents no linear correlation. Values of 1 and À1 represent total positive and negative linear correlation respectively.
Statistical analysis of cardiac biomarkers was conducted slightly differently due to the absence of baseline measurements. Analysis of biomarker samples was done at 24, 48 and 72 h post-dosing. A random intercept model that accounts for the correlation between the measurements within an experiment was applied. The RI model is fitted by considering the experiment as a random factor and dose group as a fixed factor. Each of the dose groups was then compared with the vehicle group using a Dunnett's test at each of the time points. A significance level of P < 0.05 was considered to identify which treatments were statistically significantly different from the time-matching vehicle group.
Microarray set-up and analysis
Treated cardiomyocytes were lysed using RLT buffer (Qiagen) and RNA extracted with the RNeasy 96 kit (p/n 74 181 Qiagen). All microarray-related steps for target preparation, including the amplification of total RNA and labelling, were carried out as described in the GeneChip®3 0 IVT Express Kit User Manual (Affymetrix 2004). Biotin-labelled target samples were hybridized to GeneChip® Human Genome HG-U219 Array containing probes for approximately 18 k genes. Target hybridization was processed on the GeneTitan® Instrument according to the instructions provided in the User Guide for Expression Array Plates (P/N 702933). Images were analysed using the GeneChip® Command Console Software (AGCC) (Affymetrix).
All data were processed using the statistical computing R-programme (R version 3.2.2) (R Development Core Team, 2006) and Bioconductor tools (Gentleman et al., 2004) . The gene expression values were normalized using RMA (Irizarry et al., 2003) . Grouping of the individual probes into genespecific probe sets was performed based on Entrez Gene using the metadata package hgu219hsentrezg (version 20.0.0) (Dai et al., 2005) . The Pearson correlation between gene expression and each of the functional biomarker readouts, in log scale, was calculated based on all hiPS-CM samples within this study. The correlation P-value for the genes highly expressed in human ventricle, that is, minimal log 2 intensity across the ventricle samples larger than 7, was the basis to identify the associated biological processes using MLP (Raghavan et al., 2006) . The biological processes are defined by the Gene Ontology Consortium (Ashburner et al., 2000) .
Results
Contractile motion properties of hiPS-CMs
Video microscopy-based motion field imaging enabled measurement of functional parameters (BA, BR, CV, RV, CRD) from a synchronously beating network of hiPS-CMs. hiPS-CMs under baseline (non-treated) conditions showed a BR of 108 ± 12 beats·min À1 , a CRD of 406 ± 15 ms and a CV of 22.7 ± 3.1 μm·s À1 (n = 60, mean ± SD). Next, we evaluated the correlation between the functional parameters under baseline (non-treated) conditions (Figure 2 ). CRD and BR showed a strong negative correlation with a Pearson correlation coefficient r = À0.756, similar to that reported previously for single hiPS-CMs (Hayakawa et al.,
Figure 2
Correlation between motion field imaging-derived contractile properties of hiPS-CMs. (A-D) Relationship between relaxation velocity (RV), contraction velocity (CV), contraction-relaxation duration (CRD) and beat rate (BR) under control conditions. Data are expressed as individual experiments (n = 60) with correlation being evaluated using the Pearson correlation coefficient r.
Figure 3
Chronic effects on motion waveforms of hiPS-CMs. Examples of averaged motion waveforms show the velocity of contraction-relaxation motions of hiPS-CMs as a function of time. Vehicles and ebastine are compared with cardiotoxic drugs associated with cardiac adverse liabilities (arsenic trioxide, doxorubicin and panobinostat). Effects on waveform morphology are shown at baseline (black) and after 24 h (grey) and 72 h (red) of chronic drug exposure.
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Chronic drug-induced adverse effects on contractile motion of hiPS-CMs
We assessed chronic drug-induced effects on the contractile motion properties of hiPS-CMs. Figure 3 shows averaged motion waveforms representing the CV and RV characteristics of hiPS-CMs at baseline (black), 24 h (grey) and 72 h (red) of compound treatment. Vehicles showed no time-related changes in waveform morphology and 'contractile' parameters with the exception of decreased RV and increased CRD at 72 h. Ebastine at 100 nM (negative control) did not significantly alter the contractile properties of hiPS-CMs, with the exception of a transient decrease in BR (4 h) and CV (12 h) ( Figure 4) . Furthermore, no changes were observed in the CRD of hiPS-CMs ( Figure S1 ). In contrast, drugs associated with adverse cardiac effects caused concentration-and time-dependent changes in the contractile function of hiPS-CMs. Arsenic trioxide significantly decreased BA, BR and CV (starting from 4 to 12 h) at a concentration of 10 μM. Furthermore, at 3 μM, there was a trend towards a decreased CV at 72 h. It is most likely that prolonged (>72 h) chronic treatment at 3 μM would show more pronounced effects on hiPS-CMs. Doxorubicin already affected beating (BR, BA) and contractile properties (CV) at 1 μM with higher concentrations eventually leading to beating arrest (Figure 4) . Interestingly, arsenic (10 μM) and doxorubicin (1 μM) caused a transient increase in BR, followed by a decrease in BR together with a decrease in BA and CV. A similar increase in BR upon doxorubicin exposure has been reported by others (Chaudhari et al., 2015) . This early transient effect is possibly an initial response of hiPS-CMs to compensate for cardiotoxicity in an attempt to sustain their physiological or metabolic function. Panobinostat induced delayed effects in the form of decreased BR (Figure 4 ) and shortening of CRD at 24 h ( Figure S1 ). At later time points, the waveform morphology changed with occasional observations of arrhythmia-like events (Figure 3) . Interestingly, after 12 h, both concentrations of panobinostat significantly increased CV. Whereas, at 10 nM, this effect persisted until 72 h; 100 nM panobinostat strongly decreased the CV together with a decrease in BA from 48 h onwards, eventually leading to beating arrest (Figure 4 ).
Figure 4
Drug-induced effects on contractile motion properties of hiPS-CMs. Video-microscopy-based concentration-dependent effect of compounds on the baseline-normalized beat area (BA), beat rate (BR) and contraction velocity (CV) as a function of time. Data are expressed as means ± SEM (n = 10 for vehicle; n = 5 for drug treatments). *P < 0.05, differences between treatments and time-matched vehicles; repeated measures ANOVA.
Drug-induced cardiotoxicity assessment in hiPS-CMs BJP Relationship between contractile motion parameters and different mechanisms of cardiotoxicity All the cardiotoxic drugs tested caused adverse effects on the contractile properties of hiPS-CMs, as detected by motion field imaging analysis. To further evaluate the contractile motion parameters, we analysed the relationship between baseline-normalized CV as a function of baseline-normalized BR 24 h after dosing. Figure 5A shows that hiPS-CMs responded differently to the various drugs, implying different mechanisms of cardiotoxicity. Panobinostat effects were mainly concentrated in the upper left zone ( Figure 5A ), indicating a decrease in BR combined with a slight increase in CV after 24 h. In contrast, doxorubicin and arsenic displayed a Figure 6 Drug-induced effects of cardiotoxic drugs on cardiac biomarkers. The release of cTnI, heart FABP3 and NT-proBNP was analysed from cell medium at 24, 48 and 72 h of chronic drug treatment. Concentrations of each biomarker are expressed as means ± SEM (n = 10 for vehicle; n = 5 for drug treatments). *P < 0.05, indicating significant differences between treatments and time-matched vehicles; random intercept analysis. Note that the scale of the y-axis for cTnI levels is different for doxorubicin compared with the other drugs.
Figure 5
Relationship between drug-induced changes in contractile motion properties. Relationship between baseline-normalized contraction velocity (CV) plotted as function of (A) beat rate (BR) and (B) beat area (BA). Data are shown for individual experiments 24 h post-dosing. Vehicles and ebastine are compared with the cardiotoxic drugs. Data points are based on n = 10 for vehicles and n = 5 for drug treatments.
decreased effect on CV, while the effect on BR varied during this early (24 h) stage of cardiotoxicity. Furthermore, there was no correlation between changes in CV and BR during the cardiotoxicity induced by compound treatments ( Figure 5A ) as with vehicle treatments (S2). Figure 5B shows the relationship between CV and BA, where as expected, a decrease in BA was associated with a decrease in CV.
Release of cardiac biomarkers during cardiotoxic conditioning of hiPS-CMs
In addition to measuring contractile motion, we evaluated the release of cardiac biomarkers associated with drug-induced toxicity by collecting medium samples from the same experiment (well). Vehicles showed a relatively stable, low-level release of cTnI and FABP3 during the experiment, whereas the release of NT-proBNP in vehicle-treated preparations was at levels similar to drug-treated preparations and varied over time ( Figure 6 ). Doxorubicin triggered a strong increase in FABP3 and cTnI levels at each time point (Figures 6, 7) . Interestingly, whereas 1 μM showed a steady-state release of FABP3 and cTnI through 48 h, higher concentrations (10-50 μM) showed a decreased release in both biomarkers after 72 h. This decrease in cTnI and FABP3 at the later stage most likely reflects the cytotoxic effects at 10 to 50 μM, as can be observed from video microscopy imaging (S3). As a result, after each medium exchange (Figure 1 ), the number of viable cells is decreased, resulting in a smaller amount of cTnI or FABP3 released into medium. Arsenic trioxide only induced a modest increase in FABP3 at 72 h, accompanied by a decrease in NT-proBNP. Panobinostat induced an increased release of FABP3 between 24 and 72 h at the highest concentration tested, 100 nM, with a concurrent decrease in NT-proBNP, whereas cTnI levels did not increase. In contrast, ebastine produced no significant changes in the release of biomarkers compared with vehicles ( Figure 6 ).
Relationship between cardiac biomarkers and contractile motion in hiPS-CMs
To further evaluate the role of cTnI and FABP3, we compared the magnitude of release (as fold change) during cardiotoxic treatments relative to vehicles (Figure 7) . Doxorubicin treatments caused a marked increase in the levels of both biomarkers in the medium compared with vehicle, although cTnI showed an overall stronger response. Early effects (24 h) at 1 μM reflected similar responses of cTnI and FABP3. At higher concentrations, with obvious effect on the viability of hiPS-CMs cultures (S3), cTnI levels in the medium were more strongly elevated (~20-to 60-fold increase). Panobinostat caused an increased release of FABP3, in particular from 48 h onwards. At 72 h, 2/5 (10 nM) and 5/5 experiments (100 nM) showed increased release of FABP3 compared with vehicle treatments. In contrast, cTnI levels were not elevated in medium at 72 h. For arsenic trioxide, certain experiments showed an increased release of cTnI and FABP3 only at 72 h. However, these effects were less obvious compared with the other two cardiotoxic drugs.
Next, we evaluated the relationship between biomarkers (cTnI and FABP3) and contractile motion properties (CV) of hiPS-CMs. Figure 8A and B shows the relationship at 24 h, a time point where functional parameters begin to be altered during drug-induced cardiotoxicity. Interestingly, for doxorubicin, we noticed an apparent correlation between changes in CV and the cardiac biomarkers. In contrast, the relationship for panobinostat was less obvious, whereas for arsenic (10 μM), the CV was strongly decreased without apparent changes in biomarker release. At 48 h, decreased CV became more pronounced after exposure to 100 nM panobinostat, and these effects were accompanied by an increase in FABP3 release ( Figure 8C ). However, no such correlation for
Figure 7
Comparison between the release of cTnI and FABP3 upon drug-induced cardiotoxicity. The release of cTnI and FABP3 into the medium at 24, 48 and 72 h after dosing. Data are expressed as fold changes normalized against time-matched vehicle treatments. The values for both biomarkers originate from the same experiments (n = 5).
Drug-induced cardiotoxicity assessment in hiPS-CMs BJP panobinostat was observed between the CV and cTnI ( Figure 8D ).
Drug-induced transcriptional changes for cardiac-related genes
To evaluate drug-induced transcriptional changes in hiPS-CMs, we determined the expression of relevant genes from hiPS-CMs collected immediately after the end of experiments (72 h post dosing). Firstly, we compared specific structural cardiac genes expected to be possibly affected by cardiotoxicity. Figure 9 shows log 2 expression levels of the three cardiac injury biomarker genes TNNI3, FABP3 and NPPB together with MYH7, GJA1 and GJC1. With the ebastine treatments, all the genes showed the same expression as vehicle treatments. Panobinostat is an epigenetic drug that can strongly modify the transcriptional profile of cells. Indeed, panobinostat showed a concentration-dependent downregulation of all six cardiac genes. Doxorubicin resulted in a down-regulation of TNNI3, GJA1 and GJC1, whereas the expression of other genes was less obvious. Arsenic trioxide only caused effects at 10 μM, similar to the readout from contractile motion analysis.
Based on the correlation between gene expression and release of cardiac biomarkers from Figure 6 , we identified the biological processes supporting these (Table S1 ). cTnI release was strongly related to mitochondrial translation. These pathways were also associated with NT-proBNP and FABP3 release. Furthermore, FABP3 release was also associated with heart morphogenesis, suggesting a possible relationship with cardiac morphology or plasticity.
Discussion
Detecting different mechanisms of chronic cardiac liabilities in hiPS-CMs
Risk assessments of chronic cardiac liabilities are generally deferred to later phases of development as part of the standard in vivo toxicity tests. Examination of the effects of chronic drug exposure in hiPS-CM cultures allows the risk of cardiac liablities of compounds to be assessed at earlier stages, hence accelerating and improving the development of safer drugs. In this study, we monitored the functional capacities of hiPS-CMs together with serum-based protein biomarkers and gene expression. To evaluate the ability of video microscopy-based motion field imaging to detect chronic drug-induced effects (72 h exposure) on contractile properties of hiPS-CMs, we tested three drugs (doxorubicin, arsenic and panobinostat) known to induce cardiotoxicity on chronic exposure, although through different mechanisms of action. Our study shows that video microscopy-based motion field imaging is able to detect drug-induced effects on the contractile properties of hiPS-CMs over longer periods. Furthermore, the non-invasive visual observation of the cells, the relatively high-throughput (96-well format) and ability to detect effects of chronic exposure and opportunities for additional follow-
Figure 8
The relationship between drug-induced changes in contractile parameters and the release of cardiac biomarkers. The relationship between baseline-normalized contraction velocity (CV) plotted as a function of FABP3 and cTnI at 24 h (A,B) and 48h (C,D) after dosing. Vehicles and ebastine (circles) are compared with the cardiotoxic drugs (squares). Data points are based on n = 10 for vehicles and n = 5 for drug treatments.
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up approaches, such as immunohistochemistry, facilitates the efficient evaluation of toxic or beneficial mechanisms of compounds on cardiomyocytes.
Panobinostat is a histone deacetylase (HDAC) inhibitor with several reports of dose-related (free C max around 10-100 nM) cardiac adverse events in the form of atrial fibrillation, QT prolongation, torsades de pointes and congestive cardiac failure in the clinic (DeAngelo et al., 2013; Sharma et al., 2013) . Our results show that panobinostat (around free C max ) induces delayed (≥12 h) cardiac adverse effects on hiPS-CMs, causing a decreased BR together with increased CV (Figure 4 ) and a shortening of the CRD ( Figure S1 ). Furthermore, arrhythmic behaviour was observed at 100 nM, in line with our previous findings with panobinostat in hiPS-CMs (Kopljar et al., 2016) . Delayed cardiovascular side effects have been reported for panobinostat in preclinical dog studies, where QTc prolongation was noticed 8-9 h after the first oral dose (Spence et al., 2016) . Both the time onset and the effective concentrations (free C max around 20 nM) are in line with our results in hiPS-CMs. Furthermore, we observed that arrhythmic behaviour in hiPS-CMs caused additional arrhythmic motions within the relaxation process (Figure 3 ), which could be related to the QTc prolongation in dogs. Interestingly, certain HDAC inhibitors are able to improve cardiac dysfunction induced by pressure overload in mice, whereas others have opposite effects, exacerbating cardiac remodelling and dysfunction (Ma et al., 2016) . Despite the fact that CV is not a direct measurement of contractility, these findings could possibly explain the concentration-and time-dependent opposite effects of panobinostat on CV that we observed in hiPS-CMs (Figure 4 ).
Arsenic trioxide is used for the treatment of acute promyelocytic leukaemia, but patients can develop chronic QT prolongation and ventricular arrhythmia (Ohnishi et al., 2000) . Environmental exposure to arsenic also causes chronic cardiotoxicity (Alamolhodaei et al., 2015) . In our study, arsenic trioxide decreased the contractile function and the beating of hiPS-CMs at a concentration (10 μM) comparable to its oral C max (Yamauchi et al., 2004 ) and up to 20-fold C max (Fox et al., 2008) observed with intravenous administration of arsenic in the clinic. Furthermore, 3 μM produced a gradual decrease in CV with continued exposure, suggesting an increased sensitivity of hiPS-CMs to arsenic with longer incubation periods (e.g. towards 5-6 days). The mechanisms behind arsenic-derived cardiotoxicity are considered to be driven by increased ROS production, leading to chronic cardiotoxicity (Alamolhodaei et al., 2015) . Additional suggested mechanisms, possibly secondary to ROS, involve the modulation of calcium currents and hERG trafficking (Ficker et al., 2004) . The complexity of arsenic-induced cardiovascular risks is further demonstrated by the different effects on action potentials of isolated cardiac tissues from various species (Lu et al., 2012) . Nevertheless, the majority of studies have reported cardiac adverse effects between 3-10 μM, as we have observed in hiPS-CMs.
Doxorubicin is a widely used anthracycline chemotherapy agent that is associated with dose-related chronic cardiotoxicity in the form of dilative cardiomyopathy, congestive heart failure (Swain et al., 2003) and cardiac electrophysiological abnormalities (Nousiainen et al., 1999; Rudzinski et al., 2007) . The molecular mechanisms that account for doxorubicin-induced cardiotoxicity are
Figure 9
Drug-induced transcriptional changes for cardiac-related genes. The y-axis represents the log 2 intensity for TNNI3, FABP3, NPPB, MYH7, GJA1 and GJC1 as a function of concentration of the compound. Gene expression levels (log 2 intensities) of cardiac genes related to structural (TNNI3, FABP3, NPPB, MYH7) and functional (GJA1, GJC1) properties in vehicle-treated hiPS-CMs (n = 8) compared with cardiotoxic treatments and the negative control ebastine (n = 5).
multifactorial, resulting in mitochondrial dysfunction, apoptosis and myocardial damage (Carvalho et al., 2014) . In our study, doxorubicin caused delayed effects on the contractile properties of hiPS-CMs at 1 μM (free C max ), whereas higher concentrations displayed acute and more severe effects resulting in cessation of beating arrest and myocardial injury. These findings are in accordance with previously reported doxorubicin-induced effects on human stem cell-derived cardiomyocytes using impedance-based technologies (Nguemo et al., 2012; Clements et al., 2015) . Furthermore, patient-specific hiPSC-CMs can replicate the predilection to doxorubicin-induced cardiotoxicity of individual patients at the cellular level (Burridge et al., 2016) . These findings further emphasize the potential translational value of hiPS-CMs to assess and evaluate drug-induced cardiotoxicity. Specific cardiac proteins (e.g. cardiac troponins) are well-established serum markers used in clinical assessment and monitoring of cardiac toxicity and myocardial injury. Here, we assessed the potential value of cTnI, FABP3 and NT-proBNP for preclinical assessment of cardiotoxicity in hiPS-CMs. As expected, the negative control drug ebastine did not induce any changes in the release of these cardiac biomarkers. In contrast, the three cardiotoxic drugs triggered various effects on biomarker release from hiPS-CMs. Doxorubicin is known to induce myocardial damage resulting in an elevated release of cardiac troponins (Adamcová et al., 2005) . Indeed, our results showed that both cTnI and FABP3 levels were significantly increased in the medium during the doxorubicin treatments. These findings are in line with other studies on doxorubicininduced troponin release in human embryonic stem cellderived cardiomyocytes (Andersson et al., 2010; Holmgren et al., 2015) . Furthermore, doxorubicin caused disruption of the hiPS-CM monolayers and a decrease in cell number ( Figure S4 ), suggesting significant myocardial injury together with an increased release of cTnI. Interestingly, an investigation of the structural cardiotoxicity in hiPS-CMs has indeed shown a correlation between drug-induced increase in cTnI release and decreased cell viability (Doherty et al., 2015) . In contrast, panobinostat and arsenic did not induce a significant increase in cTnI release, but panobinostat elevated the FABP3 levels at concentrations that also affected the contractile properties of hiPS-CMs. To our knowledge, panobinostat has not been associated with changes in cardiac troponins in the clinic, and with arsenic we are aware of only one study reporting increased troponin release during acute cardiotoxicity (Ortega Carnicer et al., 2006) , although without reporting plasma arsenic concentrations.
Hence, our findings show that cardiac biomarkers cTnI and FABP3 are released under specific cardiotoxic conditions, whereas NT-proBNP seems to be less valuable for cardiotoxicity assessment in hiPS-CMs. A comparison between cTnI and FABP3 showed that cTnI was strongly released compared with FABP3 during doxorubicin treatments. These effects were particularly prominent at 10-50 μM doxorubicin, together with decreased contractile parameters BA, BR and CV. Interestingly, cTnI and FABP3 showed a similar response to 1 μM doxorubicin at 24 h, suggesting that the early onset of doxorubicin-induced cardiotoxicity can be predicted by both biomarkers. In contrast, panobinostat-induced cardiac liabilities were well detected by FABP3 release, whereas it had no obvious effect on cTnI. The release of FABP3 was also related to a decreased CV at 48 h, suggesting that FABP3 might be a predictive biomarker for panobinostat-induced cardiotoxicity in hiPS-CMs. Correlations between gene expression and release of cardiac biomarkers showed that cTnI was most significantly related to mitochondrial translation processes, which are associated with cellular functioning and cellular stress signalling (Suhm and Ott, 2016) .
Thus, our results suggest that FABP3 may be a better predictive biomarker for detection of cardiac adverse effects at a structural level than cTnI in hiPS-CMs. Two possibly related explanations may underlie these differences between FABP3 and cTnI responses. Firstly, FABP3 could be an earlier marker of myocardial damage than cTnI. Indeed, clinical studies have shown that increased levels of human FABP (or FABP3) can be detected earlier and with higher sensitivity in patients with acute myocardial infarction compared with cTnI (Cubranic et al., 2012; McMahon et al., 2012) . This assumption is supported by studies on human autopsy cases showing that FABP leakage already occurs early after myocardial infarction in the absence of myocyte necrosis (Meng et al., 2006) . Secondly, FABP3 might be a sensitive marker for various cardiovascular risks, beyond acute myocardial injury. Indeed, a large population study showed that higher serum levels of FABP3 are associated with a great number of cardiovascular risks, suggesting that it could predict overall cardiovascular mortality within a general population (Otaki et al., 2014) . However, cTnI seems to be a more sensitive biomarker for myocardial damage based on our functional, biomarker and transcriptional data, and therefore, a combined assessment of cTnI and FABP3 could be a valuable surrogate to evaluate chronic cardiotoxicity in hiPS-CMs.
Limitations and future perspectives
Although video-microscopy motion waveform analysis appears to be a valuable indicator for contractile kinetics in hiPS-CMs, which can be seen as an 'index of contractile function', the platform does not allow direct quantitative assessment of fractional shortening and force generation kinetics. Furthermore, these cells are not studied under a condition of constant stress/tension as in the native heart. hiPS-CMs show great potential as a human-based in vitro model for cardiac de-risking, but certain limitations still need to be taken into consideration. For example, the functional readouts from an in vitro model (e.g. hiPS-CMs) are lacking direct correlates to in vivo contractile measures. Nevertheless, hiPS-CMs are still related to key cardiac cellular functions that ultimately form the basis for in vivo functional effects. Furthermore, the immature fetal phenotype of hiPS-CMs compared with human adult cardiomyocytes might possibly limit extrapolations to the native adult cardiac tissue. This concern might ideally be addressed through validation/experiments conducted in parallel in adult human cardiomyocyte systems. However, such an approach is currently hindered by a limited availability of human native cardiac samples. Moreover, there are potential BJP I Kopljar et al.
issues concerning the impacts of variability in donor source tissue as well as variations in quality and time to availability for experimental use. Future validation studies between hiPS-CMs and human native cardiac models will shed further light on the strengths and limitations of hiPS-CMs as a model to predict both acute as well as chronic cardiac liabilities in humans.
Conclusions
In conclusion, our results indicate that video microscopybased motion waveform imaging is capable of detecting chronic drug-induced changes in hiPS-CMs over longer periods (e.g. several days). Therefore, contractile motion analysis of hiPS-CMs could potentially improve and accelerate cardiovascular de-risking of compounds at earlier stages of drug discovery, avoiding unexpected delays in development and limitations of use in patients. Furthermore, we showed that analysis of FABP3 and cTnI release might be a valuable surrogate to detect diverse mechanisms of drug-induced cardiotoxicity in hiPS-CMs.
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http://doi.org/10.1111/bph.13713 Figure S1 Drug-induced effects on the relaxation velocity and contraction-relaxation duration of hiPS-CMs. Concentration-dependent effect of compounds on the baseline-normalized relaxation velocity (RV) and contraction-relaxation duration (CV) as a function of time. Data are expressed as means ± SEM (n = 10 for vehicle; n = 5 for drug treatments). *P < 0.05, differences between treatments and time-matching vehicles; repeated measures ANOVA. +: CRD could not be determined due to low signal/noise ratio or beat arrest. Figure S2 Relationship between time-related changes in contraction velocity and beat rate. Figure S3 Doxorubicin-induced effects on the cell viability of hiPS-CMs. Video microscopy images showing a concentration-and time-dependent decrease in number of cells upon doxorubicin treatment. In comparison, vehicles did not induce any changes in hiPS-CM monolayers. Per treatment, the baseline, 24 h and 72 h images represent the same region of interest. Table S1 cTnI. FABP3. NT-proBNP.
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